Priscila Aparecida Correa Freitas

Dr. Priscila Aparecida Correa Freitas

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
PFPriscila Aparecida Correa Freitas
Priscila Aparecida Correa Freitas
LELethicia Rozales Ehlert
Lethicia Rozales Ehlert
JCJoiza Lins Camargo
Joiza Lins Camargo
Diabetes mellitus (DM) is a chronic and metabolic disease that presents a high global incidence. Glycated hemoglobin (A1C) is the reference test for long-term glucose monitoring, and it exhibits an association with diabetic chronic complications. However, A1C is not recommended in clinical situations which may interfere with the metabolism of hemoglobin, such as in hemolytic, secondary or iron deficiency anemia, hemoglobinopathies, pregnancy, and uremia. The glycated albumin (GA) is a test that reflects short-term glycemia and is not influenced by situations that falsely alter A1C levels. GA is the higher glycated portion of fructosamine. It is measured by a standardized enzymatic methodology, easy and fast to perform. These laboratory characteristics have ensured the highlight of GA in studies from the last decade, as a marker of monitoring and screening for DM, as well as a predictor of long-term outcomes of the disease. The aim of this review was to discuss the physiological and biochemistry characteristics of the GA, as well as its clinical utility in DM.

13 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GCGabriela Cavagnolli
Gabriela Cavagnolli
APAna Laura Pimentel
Ana Laura Pimentel
PFPriscila Aparecida Correa Freitas
Priscila Aparecida Correa Freitas
JGJorge Luiz Gross
Jorge Luiz Gross
JCJoiza Lins Camargo
Joiza Lins Camargo
Disparities in HbA1c levels have been observed among ethnic groups. Most studies were performed in patients with diabetes mellitus (DM), which may interfere with results due to the high variability of glucose levels. We conducted a systematic review and meta-analysis to investigate the effect of ethnicity on HbA1c levels in individuals without DM. This is a systematic review with meta-analysis. We searched MEDLINE and EMBASE up to September 2016. Studies published after 1996, performed in adults without DM, reporting HbA1c results measured by certified/standardized methods were included. A random effects model was used and the effect size was presented as weighted HbA1c mean difference (95% CI) between different ethnicities as compared to White ethnicity. Twelve studies met the inclusion criteria, totalling data from 49,238 individuals. There were significant differences between HbA1c levels in Blacks [0.26% (2.8 mmol/mol); 95% CI 0.18 to 0.33 (2.0 to 3.6), p <0.001; I2 = 90%, p <0.001], Asians [0.24% (2.6 mmol/mol); 95% CI 0.16 to 0.33 (1.7 to 3.6), p <0.001; I2 = 80%, p = 0.0006] and Latinos [0.08% (0.9 mmol/mol); IC 95% 0.06 to 0.10 (0.7 to 1.1); p <0.001; I2 = 0%; p = 0.72] when compared to Whites. This meta-analysis shows that, in individuals without DM, HbA1c values are higher in Blacks, Asians, and Latinos when compared to White persons. Although small, these differences might have impact on the use of a sole HbA1c point to diagnose DM in all ethnic populations.

1 May 2015 in Clinica Chimica Acta
Verified
Journal Article
Closed access
GCGabriela Cavagnolli
Gabriela Cavagnolli
APAna Laura Pimentel
Ana Laura Pimentel
PFPriscila Aparecida Correa Freitas
Priscila Aparecida Correa Freitas
JGJorge Luiz Gross
Jorge Luiz Gross
JCJoiza Lins Camargo
Joiza Lins Camargo

21 October 2016 in Analytical Methods
Verified
Journal Article
Closed access
PDF file
PFPriscila Aparecida Correa Freitas
Priscila Aparecida Correa Freitas
LELethicia Rozales Ehlert
Lethicia Rozales Ehlert
JCJoiza Lins Camargo
Joiza Lins Camargo
Glycated albumin (GA) has attracted considerable interest as an alternative laboratory marker for glycated haemoglobin (A1C). GA reflects a short-term glucose monitoring, and it is not influenced by haemoglobin metabolism. Recently, there have been reports of new enzymatic methodologies for GA measurement. The aim of this study was to perform a comparison between two GA enzymatic assays commercially available in Brazil (Crystal Chem® and Diazyme®) with samples from adult patients with and without diabetes (N = 85), following CLSI recommendations. For the study, we assessed the diabetic status of patients according to their A1C levels, and we excluded those with clinical conditions that could interfere with GA or A1C levels. We observed a very strong and significant correlation (R = 0.91, p < 0.001) between the methods. The Bland–Altman plot showed a good overall agreement between the GA results (1.2% ± 2.45%; mean of absolute differences ± SD), and the Passing–Bablok regression indicated no differences between the assays. The Diazyme® GA kit presented a lower analytical imprecision (CV% inter = 8.7%) than Crystal Chem® (CV% inter = 10.0%). GA and A1C showed a moderate correlation when measured by the Diazyme® or Crystal Chem® kits (R = 0.71 and R = 0.63; p < 0.001, respectively). To the best of our knowledge, this is the first study to evaluate the Crystal Chem® kit. Diazyme® and Crystal Chem® GA assays showed a good correlation with a small difference. The association between GA and A1C demonstrates that this new marker may be a useful alternative when A1C results are unreliable.

1 January 2017 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
GFGislaine Furlanetto
Gislaine Furlanetto
AAAna Paula Alegretti
Ana Paula Alegretti
MFMariela Granero Farias
Mariela Granero Farias
PFPriscila Aparecida Correa Freitas
Priscila Aparecida Correa Freitas
GLGustavo Muller Lara
Gustavo Muller Lara
FPFabiane Spagnol Pedrazzani
Fabiane Spagnol Pedrazzani
Immunosuppression of T lymphocytes is required for preventing acute rejection after transplantation and for the treatment of chronic autoimmune and inflammatory diseases. The laboratory monitoring for this therapy is the measurement of T cells by immunophenotyping, aiming the target value of less than 20 cells per µL. To establish a cut-off point for the total number of lymphocytes in the automated blood cell count that reflects less than twenty T cells µL by immunophenotyping. We studied and evaluated 242 kidney transplant patients that had results of automated blood cell count and quantification of T cells by immunophenotyping technique. The patients were divided into two groups, depending on the T lymphocyte immunophenotyping rates established by lower and higher than 20 cells per µL. After, we evaluated the cut-off point for lymphocytes in the blood cell count with a specificity of 100% to exclude patients with high levels of T lymphocytes. We found that the cut-off point of 70 lymphocytes per µL obtained by automated blood cell count showed 100% of specificity to exclude patients with T-cell counts higher than 20 cells per µL by immunophenotyping. The results found in this study may be helpful to monitor the immunosuppressive therapy in kidney transplant patients in places where a flow cytometer is not available, or when this equipment is not present in the full routine.

1 January 2021 in Revista Paulista de Pediatria
Verified
Journal Article
Open access
PDF file
MFMariela Granero Farias
Mariela Granero Farias
PFPriscila Aparecida Correa Freitas
Priscila Aparecida Correa Freitas
FSFabiane Spagnol
Fabiane Spagnol
MSMeriene Viquetti de Souza
Meriene Viquetti de Souza
AAAna Paula Alegretti
Ana Paula Alegretti
LDLiane Daudt
Liane Daudt
Objective: To describe the case of a child who presented hemophagocytic lymphohistiocytosis (HLH) associated with acute monocytic leukemia after chemotherapy, with hemophagocytosis caused by leukemic cells. Case description: In a university hospital in Southern Brazil, a 3-year-old female was diagnosed with acute monocytic leukemia with normal karyotype. The chemotherapy regimen was initiated, and she achieved complete remission six months later, relapsing after four months with a complex karyotype involving chromosomes 8p and 16q. The bone marrow showed vacuolated blasts with a monocytic aspect and evidence of hemophagocytosis. The child presented progressive clinical deterioration and died two months after the relapse. Comments: HLH is a rare and aggressive inflammatory condition characterized by cytopenias, hepatosplenomegaly, fever, and hemophagocytosis in the bone marrow, lymph nodes, spleen, and liver. Although rare, malignancy-associated HLH (M-HLH) is fatal. The patient in this case report met five out of the eight established criteria for HLH. The evolution of the patient’s karyotype, regardless of the diagnostic profile, seemed secondary to the treatment for acute monocytic leukemia. In this case, the cytogenetic instability might have influenced the abnormal behavior of leukemic cells. This is a rare case of HLH in a child with acute monocytic leukemia.